Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$16.07 +2.6%	$14.98	$9.57 ▼ $30.41	$2.16B	0.96	1.53 million shs	1.44 million shs
BHC Bausch Health Cos	$6.43 +0.7%	$5.11	$3.96 ▼ $9.85	$2.36B	0.28	2.61 million shs	2.32 million shs
NAMS NewAmsterdam Pharma	$18.45 +0.7%	$18.68	$14.06 ▼ $27.29	$2.06B	-0.03	707,775 shs	755,738 shs
RLAY Relay Therapeutics	$3.32 +1.8%	$3.11	$1.78 ▼ $10.72	$558.91M	1.59	2.08 million shs	1.18 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+2.62%	+2.88%	+4.55%	+16.28%	-38.80%
BHC Bausch Health Cos	+0.71%	+3.75%	+40.13%	-0.93%	-5.38%
NAMS NewAmsterdam Pharma	+0.65%	+1.37%	+8.47%	-15.21%	-6.58%
RLAY Relay Therapeutics	+1.84%	-1.19%	+16.49%	+22.06%	-46.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.6903 of 5 stars	3.4	1.0	3.4	3.0	2.5	0.0
BHC Bausch Health Cos	3.6171 of 5 stars	1.9	2.0	4.0	3.3	3.3	0.6
NAMS NewAmsterdam Pharma	3.0581 of 5 stars	3.5	2.0	0.0	2.6	5.0	0.0
RLAY Relay Therapeutics	2.4827 of 5 stars	3.4	2.0	0.0	2.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	172.02% Upside
BHC Bausch Health Cos	1.86	Reduce	$7.42	15.43% Upside
NAMS NewAmsterdam Pharma	3.00	Buy	$42.89	132.46% Upside
RLAY Relay Therapeutics	2.83	Moderate Buy	$17.67	432.13% Upside

Current Analyst Ratings Breakdown

Latest RLAY, NAMS, BHC, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	NAMS NewAmsterdam Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
6/12/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
6/10/2025	NAMS NewAmsterdam Pharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$44.00
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $40.00
5/7/2025	RLAY Relay Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $10.00
5/2/2025	BHC Bausch Health Cos	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$8.50 ➝ $10.00
4/17/2025	RLAY Relay Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$4.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	625.15	N/A	N/A	$1.54 per share	10.44
BHC Bausch Health Cos	$9.63B	0.25	$7.84 per share	0.82	($0.89) per share	-7.22
NAMS NewAmsterdam Pharma	$45.56M	45.46	N/A	N/A	$8.20 per share	2.25
RLAY Relay Therapeutics	$10.01M	56.86	N/A	N/A	$4.65 per share	0.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	18.42	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
BHC Bausch Health Cos	-$46M	-$0.11	N/A	1.38	N/A	-0.41%	-540.45%	5.26%	7/30/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$241.60M	-$1.88	N/A	N/A	N/A	-397.45%	-37.34%	-33.45%	8/6/2025 (Estimated)
RLAY Relay Therapeutics	-$337.71M	-$2.23	N/A	N/A	N/A	N/A	-44.17%	-39.53%	8/5/2025 (Estimated)

Latest RLAY, NAMS, BHC, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
5/5/2025	Q1 2025	RLAY Relay Therapeutics	-$0.50	-$0.46	+$0.04	-$0.46	$0.01 million	$7.68 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
BHC Bausch Health Cos	N/A	1.35	0.97
NAMS NewAmsterdam Pharma	N/A	19.98	19.98
RLAY Relay Therapeutics	N/A	19.96	19.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
BHC Bausch Health Cos	78.65%
NAMS NewAmsterdam Pharma	89.89%
RLAY Relay Therapeutics	96.98%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
BHC Bausch Health Cos	8.05%
NAMS NewAmsterdam Pharma	20.84%
RLAY Relay Therapeutics	4.87%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
BHC Bausch Health Cos	20,700	370.08 million	340.29 million	Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	88.87 million	Optionable
RLAY Relay Therapeutics	330	171.45 million	163.10 million	Optionable

RLAY, NAMS, BHC, and ARWR Headlines

Recent News About These Companies

Relay Therapeutics, Inc. (RLAY) - Yahoo Finance

June 24 at 5:58 PM | finance.yahoo.com

BofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT

June 24 at 4:18 PM | insidermonkey.com

Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.9% - Time to Sell?

June 20, 2025 | marketbeat.com

Relay Therapeutics (NASDAQ:RLAY) Stock Price Up 5.7% - Here's What Happened

June 18, 2025 | marketbeat.com

Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down - Here's What Happened

June 13, 2025 | marketbeat.com

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

June 11, 2025 | globenewswire.com

Relay Therapeutics (NASDAQ:RLAY) Trading 6.7% Higher - What's Next?

June 10, 2025 | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Moderate Buy" from Analysts

June 10, 2025 | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Sees Large Growth in Short Interest

June 5, 2025 | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by Bank of America Corp DE

June 4, 2025 | marketbeat.com

Squarepoint Ops LLC Increases Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY)

June 3, 2025 | marketbeat.com

Nuveen Asset Management LLC Increases Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY)

June 3, 2025 | marketbeat.com

Jane Street Group LLC Cuts Stock Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)

June 3, 2025 | marketbeat.com

Relay Therapeutics’ RLY-2608 Shows Promising 11-Month PFS in Breast Cancer

June 2, 2025 | msn.com

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025

June 2, 2025 | globenewswire.com

Two Sigma Investments LP Sells 199,482 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)

May 31, 2025 | marketbeat.com

Relay Therapeutics (NASDAQ:RLAY) Shares Up 5.1% - Here's What Happened

May 30, 2025 | marketbeat.com

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

May 29, 2025 | globenewswire.com

Relay Therapeutics’ SWOT analysis: ai-driven biotech stock faces pivotal year

May 29, 2025 | investing.com

Voloridge Investment Management LLC Cuts Stock Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)

May 29, 2025 | marketbeat.com

Man Group plc Buys Shares of 173,605 Relay Therapeutics, Inc. (NASDAQ:RLAY)

May 27, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLAY, NAMS, BHC, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$16.07 +0.41 (+2.62%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$16.22 +0.15 (+0.90%)

As of 08:05 AM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Bausch Health Cos NYSE:BHC

$6.42 +0.05 (+0.71%)

Closing price 06/26/2025 03:59 PM Eastern

Extended Trading

$6.50 +0.07 (+1.09%)

As of 08:18 AM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

NewAmsterdam Pharma NASDAQ:NAMS

$18.45 +0.12 (+0.65%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$18.45 +0.00 (+0.03%)

As of 06/26/2025 04:04 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Relay Therapeutics NASDAQ:RLAY

$3.32 +0.06 (+1.84%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$3.40 +0.08 (+2.41%)

As of 08:00 AM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time